Delhi HC Seeks Government Response on Ranitidine Safety Review Deadline

The Delhi High Court on Wednesday took cognizance of a public interest petition seeking expedited completion of the pending safety review of Ranitidine, a commonly prescribed medication for acid reflux and stomach-related ailments. The court has asked the Centre and relevant drug regulatory bodies to furnish their response on the plea, which seeks directions to set a definite timeline for concluding the review process.

Ranitidine, an H2-receptor antagonist, has been in widespread use across Indian households and hospitals for decades as a standard treatment for various gastrointestinal conditions. The petition highlights concerns over the prolonged delay in completing the safety assessment, which has remained pending with authorities.

The court's intervention comes as the drug regulatory system faces mounting pressure to enhance transparency and expedite reviews of medications already in circulation. The plea before the court seeks to ensure that consumers and the medical community receive timely guidance on the safety status of the medication.

The matter is now scheduled for further hearing, with the government and drug regulatory authorities expected to file detailed responses outlining their assessment timeline and findings thus far. The outcome of this petition could influence regulatory practices governing medicine safety reviews in India.